ARCA Biopharma: COVID Treatment Phase 2B Data Coming In 2nd Quarter

By Gareth Soloway of In the Money Stocks

President & Chief Market Strategist at IntheMoneyStocks • Feb 5, 2021 at 2:12 PM EST

While extremely speculative, this biotech may be worth a shot for an explosive move, if the data is positive.

ARCA Biopharma (ABIO) has a novel treatment for COVID-19 in the works. The phase 2b data will be released in the 2nd quarter. In a world of wild moves in biotechnology stocks, this little biotech is trading near its lows. When this possible treatment was announced back in early 2020, ARCA Biopharma jumped to a high of $22.00. It has now settled down around $4.75/share. With new variants of COVID-19 popping up, this virus will be with the world for decades to come. Treatments are going to be extremely important. While extremely speculative, this biotech may be worth a shot for an explosive move, if the data is positive.

(Click on image to enlarge)

Disclaimer:

All comments made by InTheMoneyStocks, LLC and its subsidiaries, instructors, and representatives are for educational and informational purposes only and should not be construed as investment advice regarding the purchase or sale of securities, or any other financial instrument of any kind. Please consult with your financial adviser before making an investment decision regarding any securities mentioned herein. InTheMoneyStocks, LLC and its representatives assume no responsibility for your trading and investment results. All information on the website was obtained from sources believed to be reliable., but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. InTheMoneyStocks, LLC, its employees, representatives and affiliated individuals may have a position or effect transactions in the securities herein and or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies. Trading of any type involves a very high degree of risk. Futures and Options trading are not suitable for all investors. Past results are not indicative of future results. InTheMoneyStocks, LLC, its subsidiaries and all affiliated individuals assume no responsibility for your trading and investment results.